Clin Mol Hepatol.
2020 Jan;26(1):1-6. 10.3350/cmh.2019.0023.
Immunologic strategies and outcomes in ABO-incompatible living donor liver transplantation
- Affiliations
-
- 1Department of Surgery, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea
- 2Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
- KMID: 2501310
- DOI: http://doi.org/10.3350/cmh.2019.0023
Abstract
- Antibody mediated rejection (AMR) after adult ABO-incompatible living donor liver transplantation (ABO-I LDLT) induced hepatic necrosis or diffuse intrahepatic biliary complications, which were related with poor graft and patient survival. Various desensitization protocols have been used to overcome these problems. Since using rituximab, the outcomes of ABO-I LDLT show a similar survival rate to those of ABO-compatible living donor liver transplantation. However, diffuse bile duct complications still occur after ABO-I LDLT. We have reviewed the past and current immune strategies for desensitization and to provide outcomes and ABO incompatibility-related complications in ABO-I LDLT.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- ABO-Incompatible Living Donor Liver Transplantation
- ABO Incompatible Living Donor Liver Transplantation: A Single Center Experience
- Overcoming high pre-transplant isoagglutinin titers using high-dose intravenous immunoglobulin, salvage plasmapheresis, and booster rituximab without splenectomy in ABO-incompatible living donor liver transplantation: a case report
- ABO incompatibility is a risk factor for cytomegalovirus infection with living donor liver transplantation
- Desensitization in HLA Incompatible Transplantation
